ReviewInternational health2018
Refocusing vector assessment towards the elimination of onchocerciasis from Africa: a review of the current status in selected countries.
Review in International health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 19 citations in OpenAlex.
- Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection.PLoS neglected tropical diseases · 2022Trial
- HISTONCHO: A dataset of intervention histories for onchocerciasis control & elimination in sub-Saharan Africa.Scientific data · 2026Article
- The interruption of transmission of onchocerciasis in Kaduna, Kebbi and Zamfara states, Nigeria: another milestone achievement.International health · 2022Article
- Article
- The Interruption of Transmission of Human Onchocerciasis by an Annual Mass Drug Administration Program in Plateau and Nasarawa States, Nigeria.The American journal of tropical medicine and hygiene · 2020Article
- Elimination of onchocerciasis in Africa by 2025: the need for a broad perspective.Infectious diseases of poverty · 2019Article
- Reaching the last mile: main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa.Infectious diseases of poverty · 2019Review
- Onchodermatitis: Where Are We Now?Tropical medicine and infectious disease · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 4 countries.
Funding
Abstract
Measures to control onchocerciasis have been in place for well over 30 years. Recently, programs have turned from disease control towards transmission elimination. The absence of infective larvae in the black fly Simulium sp. vector is central to defining elimination, and assessments of infectivity by O150 polymerase chain reaction in the vector not only provide valuable information to programs, but are also required for verification of elimination. The status of transmission in black flies was assessed in five countries in the African region during 2014 and 2015. Several of these countries were evaluated because of promising results from epidemiological studies in humans. No infective flies were found in two countries. Infective flies were found in the other three, despite the absence of infection in humans (as evaluated by skin-snip microscopy). Ongoing transmission as demonstrated in the black flies could be due to a variety of factors, including lack of treatment of hypo-endemic areas and cross-border issues. Challenges identified during the course of the entomological work suggest that there is a need for improved selection of vector collection sites and vector collection periods in order to improve fly catches. Two important challenges to achieving elimination identified were definition of the hypo-endemic zones and establishing the existence of areas of cross-border transmission occurring between countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.